I-mab (IMAB)

$1.72

+0.04

(+2.38%)

Market is closed - opens 7 PM, 25 Jun 2024

Insights on I-mab

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 2.83M → 1.10M (in $), with an average decrease of 61.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -2.97B → -95.73M (in $), with an average increase of 1293.5% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 78.5% return, outperforming this stock by 123.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.4% return, outperforming this stock by 343.3%

Performance

  • $1.67
    $1.72
    $1.72
    downward going graph

    2.91%

    Downside

    Day's Volatility :2.91%

    Upside

    0.0%

    downward going graph
  • $1.16
    $3.20
    $1.72
    downward going graph

    32.56%

    Downside

    52 Weeks Volatility :63.75%

    Upside

    46.25%

    downward going graph

Returns

PeriodI-mabSector (Health Care)Index (Russel 2000)
3 Months
-9.68%
0.9%
0.0%
6 Months
5.66%
8.7%
0.0%
1 Year
-45.1%
11.2%
0.0%
3 Years
-97.93%
17.3%
-24.2%

Highlights

Market Capitalization
138.3M
Book Value
$21.29
Earnings Per Share (EPS)
-2.43
Wall Street Target Price
26.0
Profit Margin
0.0%
Operating Margin TTM
-7062.8%
Return On Assets TTM
-23.11%
Return On Equity TTM
-63.34%
Revenue TTM
27.6M
Revenue Per Share TTM
0.33
Quarterly Revenue Growth YOY
-62.1%
Gross Profit TTM
41.6M
EBITDA
-1.2B
Diluted Eps TTM
-2.43
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for I-mab(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1411.63%

Current $1.72
Target $26.00

Company Financials

FY18Y/Y Change
Revenue
7.8M
↑ 365.39%
Net Income
-58.6M
↑ 35.07%
Net Profit Margin
-749.02%
↑ 1831.8%
FY19Y/Y Change
Revenue
4.3M
↓ 44.22%
Net Income
-208.3M
↑ 261.15%
Net Profit Margin
-4.8K%
↓ 4100.46%
FY20Y/Y Change
Revenue
236.5M
↑ 5042.23%
Net Income
72.2M
↓ 132.37%
Net Profit Margin
30.53%
↑ 4880.01%
FY21Y/Y Change
Revenue
13.8M
↓ 94.29%
Net Income
-365.9M
↓ 595.11%
Net Profit Margin
-2.6K%
↓ 2679.23%
FY22Y/Y Change
Revenue
-32.1M
↓ 351.7%
Net Income
-349.7M
↑ 3.44%
Net Profit Margin
1.1K%
↑ 3737.25%
FY23Y/Y Change
Revenue
27.6M
↓ 112.48%
Net Income
-1.5B
↓ 39.23%
Net Profit Margin
-5.3K%
↓ 6390.58%
Q1 FY22Q/Q Change
Revenue
-238.4M
-
Net Income
-303.0M
-
Net Profit Margin
127.12%
-
Q3 FY22Q/Q Change
Revenue
8.0M
-
Net Income
-161.5M
-
Net Profit Margin
-2.0K%
-
Q1 FY23Q/Q Change
Revenue
-256.8M
↓ 22147.83%
Net Income
-433.4M
↑ 1743.3%
Net Profit Margin
168.77%
↑ 2187.47%
Q2 FY23Q/Q Change
Revenue
2.8M
↓ 100.16%
Net Income
-111.5M
↓ 96.26%
Net Profit Margin
-3.9K%
↓ 4100.57%
Q1 FY24Q/Q Change
Revenue
1.1M
↓ 61.08%
Net Income
-95.7M
↓ 14.14%
Net Profit Margin
-8.7K%
↓ 4741.35%
FY18Y/Y Change
Total Assets
345.5M
↑ 131.72%
Total Liabilities
484.4M
↑ 151.37%
FY19Y/Y Change
Total Assets
248.7M
↓ 26.87%
Total Liabilities
540.0M
↑ 13.25%
FY20Y/Y Change
Total Assets
971.1M
↑ 264.52%
Total Liabilities
108.3M
↓ 81.27%
FY21Y/Y Change
Total Assets
883.4M
↓ 11.12%
Total Liabilities
163.5M
↑ 47.41%
FY22Y/Y Change
Total Assets
590.7M
↓ 27.64%
Total Liabilities
154.5M
↑ 2.28%
FY23Y/Y Change
Total Assets
2.6B
↓ 35.86%
Total Liabilities
894.8M
↓ 16.01%
Q4 FY22Q/Q Change
Total Assets
590.7M
↓ 18.39%
Total Liabilities
154.5M
↑ 9.21%
Q1 FY23Q/Q Change
Total Assets
511.1M
↓ 13.8%
Total Liabilities
155.0M
↓ 0.04%
Q2 FY23Q/Q Change
Total Assets
484.2M
↑ 0.0%
Total Liabilities
146.8M
↑ 0.0%
Q3 FY23Q/Q Change
Total Assets
2.6B
↓ 25.59%
Total Liabilities
894.8M
↓ 15.97%
Q4 FY23Q/Q Change
Total Assets
2.6B
↑ 0.0%
Total Liabilities
894.8M
↑ 0.0%
Q1 FY24Q/Q Change
Total Assets
2.6B
↑ 0.0%
Total Liabilities
894.8M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-40.8M
↑ 11.32%
Investing Cash Flow
1.4M
↓ 106.03%
Financing Cash Flow
215.2M
↑ 95.06%
FY19Y/Y Change
Operating Cash Flow
-124.3M
↑ 209.22%
Investing Cash Flow
30.4M
↑ 2136.44%
Financing Cash Flow
21.9M
↓ 89.68%
FY20Y/Y Change
Operating Cash Flow
66.5M
↓ 149.95%
Investing Cash Flow
-31.0M
↓ 195.03%
Financing Cash Flow
527.5M
↑ 2152.97%
FY21Y/Y Change
Operating Cash Flow
-152.7M
↓ 324.44%
Investing Cash Flow
-114.1M
↑ 260.18%
Financing Cash Flow
93.2M
↓ 82.74%
Q3 FY21Q/Q Change
Operating Cash Flow
-41.1M
↑ 19.84%
Investing Cash Flow
-26.8M
↓ 9.32%
Financing Cash Flow
8.4M
↓ 77.85%
Q4 FY21Q/Q Change
Operating Cash Flow
-41.6M
↑ 0.0%
Investing Cash Flow
-27.1M
↑ 0.0%
Financing Cash Flow
8.4M
↑ 0.0%
Q1 FY22Q/Q Change
Operating Cash Flow
-313.5M
↑ 650.03%
Investing Cash Flow
39.3M
↓ 244.39%
Financing Cash Flow
8.5M
↑ 0.0%
Q2 FY22Q/Q Change
Operating Cash Flow
-42.6M
↓ 85.64%
Investing Cash Flow
37.3M
↑ 0.0%
Financing Cash Flow
2.6M
↓ 67.15%

Technicals Summary

Sell

Neutral

Buy

I-mab is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
I-mab
I-mab
-4.0%
5.66%
-45.1%
-97.93%
-97.9%
Moderna, Inc.
Moderna, Inc.
-19.93%
37.06%
10.79%
-39.4%
850.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
6.92%
23.97%
34.26%
93.43%
236.95%
Novo Nordisk A/s
Novo Nordisk A/s
4.35%
38.25%
80.59%
245.4%
453.56%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
2.57%
14.98%
34.9%
144.2%
158.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
I-mab
I-mab
NA
NA
NA
0.0
-0.63
-0.23
NA
21.29
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.7
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.93
30.93
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.78
49.78
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.61
30.61
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
I-mab
I-mab
Buy
$138.3M
-97.9%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$51.5B
850.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$115.3B
236.95%
30.93
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$644.0B
453.56%
49.78
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.7B
158.93%
30.61
39.46%

Institutional Holdings

  • Hillhouse Capital Advisors, Ltd.

    8.54%
  • Caligan Partners LP

    0.94%
  • Two Sigma Advisers, LLC

    0.76%
  • Two Sigma Investments LLC

    0.71%
  • Temasek Holdings Ltd.

    0.70%
  • GSA Capital Partners LLP

    0.53%

Company Information

i-mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. it is developing felzartamab (tj202), a cd38 antibody that is in phase iii clinical trials to treat multiple myeloma and autoimmune diseases; eftansomatropin (tj101), a long-acting human growth hormone that has completed phase ii clinical trials to treat pediatric growth hormone deficiency; and olamkicept (tj301), a il-6 blocker, which is in phase ii clinical trials for the treatment of ulcerative colitis and autoimmune diseases. the company's product candidates also include enoblituzumab, a humanized b7-h3 antibody that has completed phase i clinical trials to treat head and neck cancer and other oncology diseases; efineptakin (tj107), a long-acting recombinant human il-7, which is in phase 2 clinical trials to treat glioblastoma multiforme (gbm

Organization
I-mab
Employees
220
CEO
Mr. Raj Kannan
Industry
Health Technology

FAQs